195 related articles for article (PubMed ID: 25848982)
1. Mammary gland tumor promotion by chronic administration of IGF1 and the insulin analogue AspB10 in the p53R270H/⁺WAPCre mouse model.
ter Braak B; Siezen C; Speksnijder EN; Koedoot E; van Steeg H; Salvatori DC; van de Water B; van der Laan JW
Breast Cancer Res; 2015 Feb; 17(1):14. PubMed ID: 25848982
[TBL] [Abstract][Full Text] [Related]
2. Insulin-like growth factor 1 receptor activation promotes mammary gland tumor development by increasing glycolysis and promoting biomass production.
Ter Braak B; Siezen CL; Lee JS; Rao P; Voorhoeve C; Ruppin E; van der Laan JW; van de Water B
Breast Cancer Res; 2017 Feb; 19(1):14. PubMed ID: 28173837
[TBL] [Abstract][Full Text] [Related]
3. Alternative signaling network activation through different insulin receptor family members caused by pro-mitogenic antidiabetic insulin analogues in human mammary epithelial cells.
ter Braak B; Wink S; Koedoot E; Pont C; Siezen C; van der Laan JW; van de Water B
Breast Cancer Res; 2015 Jul; 17(1):97. PubMed ID: 26187749
[TBL] [Abstract][Full Text] [Related]
4. IGF1 dependence of dietary energy balance effects on murine Met1 mammary tumor progression, epithelial-to-mesenchymal transition, and chemokine expression.
Ford NA; Nunez NP; Holcomb VB; Hursting SD
Endocr Relat Cancer; 2013 Feb; 20(1):39-51. PubMed ID: 23152442
[TBL] [Abstract][Full Text] [Related]
5. Highly specific role of the insulin receptor in breast cancer progression.
Rostoker R; Abelson S; Bitton-Worms K; Genkin I; Ben-Shmuel S; Dakwar M; Orr ZS; Caspi A; Tzukerman M; LeRoith D
Endocr Relat Cancer; 2015 Apr; 22(2):145-57. PubMed ID: 25694511
[TBL] [Abstract][Full Text] [Related]
6. Classifying the adverse mitogenic mode of action of insulin analogues using a novel mechanism-based genetically engineered human breast cancer cell panel.
ter Braak B; Siezen CL; Kannegieter N; Koedoot E; van de Water B; van der Laan JW
Arch Toxicol; 2014 Apr; 88(4):953-66. PubMed ID: 24464500
[TBL] [Abstract][Full Text] [Related]
7. Hexachlorobenzene is a tumor co-carcinogen and induces alterations in insulin-growth factors signaling pathway in the rat mammary gland.
Randi AS; Cocca C; Carbone V; Nuñez M; Croci M; Gutiérrez A; Bergoc R; Kleiman de Pisarev DL
Toxicol Sci; 2006 Jan; 89(1):83-92. PubMed ID: 16237195
[TBL] [Abstract][Full Text] [Related]
8. Nicotine promotes initiation and progression of KRAS-induced pancreatic cancer via Gata6-dependent dedifferentiation of acinar cells in mice.
Hermann PC; Sancho P; Cañamero M; Martinelli P; Madriles F; Michl P; Gress T; de Pascual R; Gandia L; Guerra C; Barbacid M; Wagner M; Vieira CR; Aicher A; Real FX; Sainz B; Heeschen C
Gastroenterology; 2014 Nov; 147(5):1119-33.e4. PubMed ID: 25127677
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of des(1-3) insulin-like growth factor 1 in the mammary glands of transgenic mice delays the loss of milk production with prolonged lactation.
Hadsell DL; Torres DT; Lawrence NA; George J; Parlow AF; Lee AV; Fiorotto ML
Biol Reprod; 2005 Dec; 73(6):1116-25. PubMed ID: 16079306
[TBL] [Abstract][Full Text] [Related]
10. In situ phosphorylation of Akt and ERK1/2 in rat mammary gland, colon, and liver following treatment with human insulin and IGF-1.
Hvid H; Fels JJ; Kirk RK; Thorup I; Jensen HE; Hansen BF; Oleksiewicz MB
Toxicol Pathol; 2011 Jun; 39(4):623-40. PubMed ID: 21558470
[TBL] [Abstract][Full Text] [Related]
11. Functional cooperation of RKTG with p53 in tumorigenesis and epithelial-mesenchymal transition.
Jiang Y; Xie X; Li Z; Wang Z; Zhang Y; Ling ZQ; Pan Y; Wang Z; Chen Y
Cancer Res; 2011 Apr; 71(8):2959-68. PubMed ID: 21385899
[TBL] [Abstract][Full Text] [Related]
12. ASPB10 insulin induction of increased mitogenic responses and phenotypic changes in human breast epithelial cells: evidence for enhanced interactions with the insulin-like growth factor-I receptor.
Milazzo G; Sciacca L; Papa V; Goldfine ID; Vigneri R
Mol Carcinog; 1997 Jan; 18(1):19-25. PubMed ID: 9022809
[TBL] [Abstract][Full Text] [Related]
13. ETV6-NTRK3-mediated breast epithelial cell transformation is blocked by targeting the IGF1R signaling pathway.
Tognon CE; Somasiri AM; Evdokimova VE; Trigo G; Uy EE; Melnyk N; Carboni JM; Gottardis MM; Roskelley CD; Pollak M; Sorensen PH
Cancer Res; 2011 Feb; 71(3):1060-70. PubMed ID: 21148487
[TBL] [Abstract][Full Text] [Related]
14. Insulin receptor (IR) pathway hyperactivity in IGF-IR null cells and suppression of downstream growth signaling using the dual IGF-IR/IR inhibitor, BMS-754807.
Dinchuk JE; Cao C; Huang F; Reeves KA; Wang J; Myers F; Cantor GH; Zhou X; Attar RM; Gottardis M; Carboni JM
Endocrinology; 2010 Sep; 151(9):4123-32. PubMed ID: 20610571
[TBL] [Abstract][Full Text] [Related]
15. Activation of insulin receptors and IGF-1 receptors in COLO-205 colon cancer xenografts by insulin and insulin analogue X10 does not enhance growth under normo- or hypoglycaemic conditions.
Hvid H; Jørgensen MS; Blume N; Slaaby R; Lützen A; Hansen BF
Diabetologia; 2018 Nov; 61(11):2447-2457. PubMed ID: 30003309
[TBL] [Abstract][Full Text] [Related]
16. Analysis of signaling pathways related to cell proliferation stimulated by insulin analogs in human mammary epithelial cell lines.
Shukla A; Grisouard J; Ehemann V; Hermani A; Enzmann H; Mayer D
Endocr Relat Cancer; 2009 Jun; 16(2):429-41. PubMed ID: 19153208
[TBL] [Abstract][Full Text] [Related]
17. Review on the in vitro interaction of insulin glargine with the insulin/insulin-like growth factor system: potential implications for metabolic and mitogenic activities.
Ciaraldi TP; Sasaoka T
Horm Metab Res; 2011 Jan; 43(1):1-10. PubMed ID: 20938889
[TBL] [Abstract][Full Text] [Related]
18. A framework for the in vitro evaluation of cancer-relevant molecular characteristics and mitogenic potency of insulin analogues.
Baricevic I; Jones DR; Roberts DL; Lutzen A; Lundby A; Worm J; Hansen BF; Renehan AG
Carcinogenesis; 2015 Sep; 36(9):1040-50. PubMed ID: 26026165
[TBL] [Abstract][Full Text] [Related]
19. A chimeric humanized single-chain antibody against the type I insulin-like growth factor (IGF) receptor renders breast cancer cells refractory to the mitogenic effects of IGF-I.
Sachdev D; Li SL; Hartell JS; Fujita-Yamaguchi Y; Miller JS; Yee D
Cancer Res; 2003 Feb; 63(3):627-35. PubMed ID: 12566306
[TBL] [Abstract][Full Text] [Related]
20. Treatment with insulin-like growth factor 1 receptor inhibitor reverses hypoxia-induced epithelial-mesenchymal transition in non-small cell lung cancer.
Nurwidya F; Takahashi F; Kobayashi I; Murakami A; Kato M; Minakata K; Nara T; Hashimoto M; Yagishita S; Baskoro H; Hidayat M; Shimada N; Takahashi K
Biochem Biophys Res Commun; 2014 Dec; 455(3-4):332-8. PubMed ID: 25446090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
